Clinical trials: Tocilizumab
Mature B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric…
- Trial name
- iMATRIX GLO (NCT05533775)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to…
- Trial name
- NCT02608112
- Testing
- Methotrexate, Tocilizumab
- Where
- 77 sites in France
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
Primary Objective: To describe the safety and tolerability, including laboratory abnormalities following a single dose of sarilumab or tocilizumab administered subcutaneously (SC) as monotherapy in Japanese patients with…
- Trial name
- NCT02404558
- Testing
- sarilumab SAR153191 (REGN88), tocilizumab
- Where
- 3 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs.
- Trial name
- NCT00996606
- Testing
- DMARDs, Tocilizumab
- Where
- 11 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis
This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of…
- Trial name
- NCT05957107
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 15 sites in China
- Volunteers
- 181 people
- Sponsor
- Beijing VDJBio Co., LTD.
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe…
- Trial name
- NCT01254331
- Testing
- tocilizumab [RoActemra]
- Where
- 6 sites in Tunisia
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with DMARDs, in patients with active rheumatoid arthritis who currently…
- Trial name
- NCT00773461
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in China
- Volunteers
- 209 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor…
- Trial name
- NCT05022927
- Testing
- ERY974, Tocilicumab, Atezolizumab
- Where
- 11 sites in Japan, Taiwan
- Volunteers
- 179 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to…
- Trial name
- NCT01010503
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- Slovakia
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA213JP.
- Trial name
- NCT00144534
- Testing
- MRA (Tocilizumab)
- Volunteers
- 115 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)
This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in patients with rheumatoid arthritis.
- Trial name
- NCT01893255
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large…
- Trial name
- NCT06624085
- Testing
- Glofitamab, Tocilizumab, Obinutuzumab
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Small Cell Lung Cancer, Neuroendocrine Carcinoma
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789.
- Trial name
- NCT05619744
- Testing
- RO7616789, Tocilizumab
- Where
- 17 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.
- Trial name
- NCT01187563
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Rheumatoid Arthritis
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time.
- Trial name
- NCT01468077
- Testing
- Tocilizumab
- Where
- 8 sites in Denmark, Iceland
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Spondylitis, Ankylosing
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis (AS) who have failed treatment with non-steroidal…
- Trial name
- NCT01209702
- Testing
- tocilizumab
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche